Cyclooxygenase-2 expression in hepatocellular carcinoma, cirrhosis and chronic hepatitis in the United States

Digestive Diseases and Sciences

Volumn 52, Issue 1, 2007, Pages 220-227

  Pazirandeh, Sassan ^a   Khettry, Urmila ^a   Gordon, Fredric D ^a   Resnick, Robert H ^b   Murray, Jessica E ^c   Sheth, Sunil G ^d  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Chemoprevention; Fibrosis; Hepatocarcinogenesis; Immunohistochemistry; Viral hepatitis

Indexed keywords

CYCLOOXYGENASE 2;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; UNITED STATES;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CYCLOOXYGENASE 2; DISEASE PROGRESSION; FEMALE; HEPATITIS, CHRONIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; UNITED STATES;

EID: 33846300715     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-9184-3     Document Type: Article

References (44)

1. El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:745-750
2. Benvegnu L, Gios M, Boccato S, Alberti A (2004) Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 53:744-749
3. Bismuth H, Majno PE, Adam R (1999) Liver transplantation for hepatocellular carcinoma. Semin Liver Dis 19:311-322
4. Llovet JM, Bruix J, Gores GJ (2000) Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy. Hepatology 31:1019-1021
5. Mor E, Kaspa RT, Sheiner P, Schwartz M (1998) Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation. Ann Intern Med 129:643-653
6. Nagasue N, Kohno H, Chang YC, Taniura H, Yamanoi A, Uchida M, Kimoto T, Takemoto Y, Nakamura T, Yukaya H (1993) Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years. Ann Surg 217:375-384
7. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56:918-928
8. Sugioka A, Tsuzuki T, Kanai T (1993) Postresection prognosis of patients with hepatocellular carcinoma. Surgery 113:612-618
9. Stadlbauer V, Schaffellner S, Kniepeiss D, Jakoby E, Stauber R, Iberer F, Tscheliessnigg KH (2004) Experiences in liver transplantation for hepatocellular carcinoma. Transplant Proc 36:195-198
10. Radaeva S, Li Y, Hacker HJ, Burger V, Kopp-Schneider A, Bannasch P (2000) Hepadnaviral hepatocarcinogenesis: in situ visualization of viral antigens, cytoplasmic compartmentation, enzymic patterns, and cellular proliferation in preneoplastic hepatocellular lineages in woodchucks. J Hepatol 33:580-600
11. Huang SN, Chisari FV (1995) Strong, sustained hepatocellular proliferation precedes hepatocarcinogenesis in hepatitis B surface antigen transgenic mice. Hepatology 21:620-626
12. Dunsford HA, Sell S, Chisari FV (1990) Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenic mice. Cancer Res 50:3400-3407
13. Ueno Y, Moriyama M, Uchida T, Arakawa Y (2001) Irregular regeneration of hepatocytes is an important factor in the hepatocarcinogenesis of liver disease. Hepatology 33:357-362
14. Hu KQ (2002) Rationale and feasibility of chemoprevention of hepatocellular carcinoma by cyclooxygenase-2 inhibitors. J Lab Clin Med 139:234-243
15. Williams CS, Mann M, DuBois RN (1999) The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18:7908-7916
16. DuBois RN, Eberhart CF, Williams CS (1996) Introduction to eicosanoids and the gastroenteric tract. Gastroenterol Clin North Am 25:267-277
17. Eberhart CE, Dubois RN (1995) Eicosanoids and the gastrointestinal tract. Gastroenterology 109:285-301
18. Fosslien E (2000) Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 37:431-502
19. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN (2000) Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 105:1589-1594
20. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93:705-716
21. Masferrer JL, Koki A, Seibert K (1999) COX-2 inhibitors. A new class of antiangiogenic agents. Ann NY Acad Sci 889:84-86
22. Kondo M, Yamamoto H, Nagano H, Okami J, Ito Y, Shimizu J, Eguchi H, Miyamoto A, Dono K, Umeshita K, Matsuura N, Wakasa K, Nakamori S, Sakon M, Monden M (1999) Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin Cancer Res 5:4005-4012
23. Koga H, Sakisaka S, Ohishi M, Kawaguchi T, Taniguchi E, Sasatomi K, Harada M, Kusaba T, Tanaka M, Kimura R, Nakashima Y, Nakashima O, Kojiro M, Kurohiji T, Sata M (1999) Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 29:688-696
24. Shiota G, Okubo M, Noumi T, Noguchi N, Oyama K, Takano Y, Yashima K, Kishimoto Y, Kawasaki H (1999) Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology 46:407-412
25. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, Fujimoto I, Inoue A, Yamazaki H et al. (1993) Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 328:1797-1801
26. Hu KQ, Tong MJ (1999) The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 29:1311-1316
27. Batts KP, Ludwig J (1995) Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 19(12):1409-1417
28. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M, Hla T (1995) Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 55:3785-3789
29. Dimberg J, Samuelsson A, Hugander A, Soderkvist P (1999) Differential expression of cyclooxygenase 2 in human colorectal cancer. Gut 45:730-732
30. Hao X, Bishop AE, Wallace M, Wang H, Willcocks TC, Maclouf J, Polak JM, Knight S, Talbot IC (1999) Early expression of cyclooxygenase-2 during sporadic colorectal carcinogenesis. J Pathol 187:295-301
31. Chapple KS, Cartwright EJ, Hawcroft G, Tisbury A, Bonifer C, Scott N, Windsor AC, Guillou PJ, Markham AF, Coletta PL, Hull MA (2000) Localization of cyclooxygenase-2 in human sporadic colorectal adenomas. Am J Pathol 156:545-553
32. Lim HY, Joo HJ, Choi JH, Yi JW, Yang MS, Cho DY, Kim HS, Nam DK, Lee KB, Kim HC (2000) Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res 6:519-525
33. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H (2000) Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42:73-78
34. Ochiai M, Oguri T, Isobe T, Ishioka S, Yamakido M (1999) Cyclooxygenase-2 (COX-2) mRNA expression levels in normal lung tissues and non-small cell lung cancers. Jpn J Cancer Res 90:1338-1343
35. Uefuji K, Ichikura T, Mochizuki H, Shinomiya N (1998) Expression of cyclooxygenase-2 protein in gastric adenocarcinoma. J Surg Oncol 69:168-172
36. Bae SH, Jung ES, Park YM, Kim BS, Kim BK, Kim DG, Ryu WS (2001) Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin Cancer Res 7:1410-1418
37. Rahman MA, Dhar DK, Yamaguchi E, Maruyama S, Sato T, Hayashi H, Ono T, Yamanoi A, Kohno H, Nagasue N (2001) Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases. Clin Cancer Res 7:1325-1332
38. Kern MA, Schubert D, Sahi D, Schoneweiss MM, Moll I, Haugg AM, Dienes HP, Breuhahn K, Schirmacher P (2002) Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 36:885-894
39. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364
40. Yoshiji H, Kuriyama S, Yoshii J, Yamazaki M, Kikukawa M, Tsujinoue H, Nakatani T, Fukui H (1998) Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells. Hepatology 28:1489-1496
41. Hsu PI, Chow NH, Lai KH, Yang HB, Chan SH, Lin XZ, Cheng JS, Huang JS, Ger LP, Huang SM, Yen MY, Yang YF (1997) Implications of serum basic fibroblast growth factor levels in chronic liver diseases and hepatocellular carcinoma. Anticancer Res 17:2803-2809
42. Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, Kojiro M (1998) Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 28:68-77
43. Miura H, Miyazaki T, Kuroda M, Oka T, Machinami R, Kodama T, Shibuya M, Makuuchi M, Yazaki Y, Ohnishi S (1997) Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J Hepatol 27:854-861
44. Lai CL, Lau JY, Wu PC, Ngan H, Chung HT, Mitchell SJ, Corbett TJ, Chow AW, Lin HJ (1993) Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 17:389-394